Systemic Treatment with Fas-Blocking Peptide Attenuates Apoptosis in Brain Ischemia
-
Published:2024-01-04
Issue:1
Volume:25
Page:661
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Chung Sungeun1, Yi Yujong1ORCID, Ullah Irfan12, Chung Kunho13, Park Seongjun1, Lim Jaeyeoung1, Kim Chaeyeon1, Pyun Seon-Hong1, Kim Minkyung1, Kim Dokyoung4ORCID, Lee Minhyung1, Rhim Taiyoun1ORCID, Lee Sang-Kyung1
Affiliation:
1. Department of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea 2. Department of Internal Medicine, Yale University, New Haven, CT 06520, USA 3. Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 4. Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
Abstract
Apoptosis plays a crucial role in neuronal injury, with substantial evidence implicating Fas-mediated cell death as a key factor in ischemic strokes. To address this, inhibition of Fas-signaling has emerged as a promising strategy in preventing neuronal cell death and alleviating brain ischemia. However, the challenge of overcoming the blood–brain barrier (BBB) hampers the effective delivery of therapeutic drugs to the central nervous system (CNS). In this study, we employed a 30 amino acid-long leptin peptide to facilitate BBB penetration. By conjugating the leptin peptide with a Fas-blocking peptide (FBP) using polyethylene glycol (PEG), we achieved specific accumulation in the Fas-expressing infarction region of the brain following systemic administration. Notably, administration in leptin receptor-deficient db/db mice demonstrated that leptin facilitated the delivery of FBP peptide. We found that the systemic administration of leptin-PEG-FBP effectively inhibited Fas-mediated apoptosis in the ischemic region, resulting in a significant reduction of neuronal cell death, decreased infarct volumes, and accelerated recovery. Importantly, neither leptin nor PEG-FBP influenced apoptotic signaling in brain ischemia. Here, we demonstrate that the systemic delivery of leptin-PEG-FBP presents a promising and viable strategy for treating cerebral ischemic stroke. Our approach not only highlights the therapeutic potential but also emphasizes the importance of overcoming BBB challenges to advance treatments for neurological disorders.
Funder
Research Foundation of Korea
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference79 articles.
1. El Amki, M., and Wegener, S. (2017). Improving Cerebral Blood Flow after Arterial Recanalization: A Novel Therapeutic Strategy in Stroke. Int. J. Mol. Sci., 18. 2. Microglia-associated neuroinflammation is a potential therapeutic target for ischemic stroke;Zhang;Neural. Regen. Res.,2021 3. Bonaventura, A., Liberale, L., Vecchie, A., Casula, M., Carbone, F., Dallegri, F., and Montecucco, F. (2016). Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int. J. Mol. Sci., 17. 4. Hui, C., Tadi, P., and Patti, L. (2018). Ischemic stroke, StatPearls Publishing. 5. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022;Feigin;Int. J. Stroke,2022
|
|